eaecaea1-2cb7-472c-b549-ff779e5e1d30
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- MYC_TARGETS_V1+0.400
- MYC_TARGETS_V2+0.400
- MYOGENESIS+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.400
- ANDROGEN_RESPONSE+0.300
- HYPOXIA+0.300
- TNFA_SIGNALING_VIA_NFKB+0.300
- UV_RESPONSE_DN+0.300
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.500
- ALLOGRAFT_REJECTION-0.400
- APICAL_SURFACE-0.300
- E2F_TARGETS-0.300
- COMPLEMENT-0.200
- G2M_CHECKPOINT-0.200
- HEME_METABOLISM-0.200
- INFLAMMATORY_RESPONSE-0.200
- OXIDATIVE_PHOSPHORYLATION-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-P3-A6T3-01A-11R-A34R-07 | — | — | 0.755 |
| 2 | 350f38a2-e597-494a-a387-975814453726 | — | — | 0.753 |
| 3 | SRR2932813 | — | — | 0.733 |
| 4 | BS_KP735TJ6 | high-grade glioma | — | 0.728 |
| 5 | TCGA-CN-5355-01A-01R-1436-07 | — | — | 0.728 |
| 6 | SRR2932825 | — | — | 0.723 |
| 7 | SRR11296891 | — | — | 0.720 |
| 8 | SRR12202487 | — | — | 0.719 |
| 9 | TCGA-FT-A3EE-01A-11R-A206-07 | — | — | 0.719 |
| 10 | TCGA-77-8130-01A-11R-2247-07 | — | cohortSQ1 | 0.715 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| MYOGENESIS | 0.400 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |